Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as-needed use?

R. Buhl, P. Kuna (Mainz, Germany; Lodz, Poland)

Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma
Session: Recent advances in our understanding of the treatment of asthma
Session type: Thematic Poster Session
Number: 3620
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Buhl, P. Kuna (Mainz, Germany; Lodz, Poland). Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as-needed use?. Eur Respir J 2007; 30: Suppl. 51, 3620

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma?
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019

The effect of smoking on severity of asthma and quality of life in patients treated with inhaled corticosteroids and long-acting b2-agonist (ICS/LABA)
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012

Budesonide/formoterol maintenance and reliever therapy compared to conventional best practice in the treatment of persistent asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 616s
Year: 2007

Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 426s
Year: 2001

Budesonide/formoterol maintenance and reliever therapy use in elderly asthma patients
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

An electronic patient decision aid comparing as-needed budesonide-formoterol combination to regular use of inhaled corticosteroid (ICS) in mild asthma: a rapid-cycle design study
Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19
Year: 2021


Budesonide/formoterol for maintenance and relief vs. higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS)
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007


Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy
Source: Eur Respir J 2007; 30: Suppl. 51, 615s
Year: 2007

Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study
Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19
Year: 2021


Influence of treatment by single combined inhaler on adherence of patients with asthma
Source: Annual Congress 2009 - Respiratory physiology
Year: 2009


Influence of age on evolution of asthma control level and treatment compliance under ICS/LABA therapy
Source: Eur Respir J 2005; 26: Suppl. 49, 382s
Year: 2005

Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004

Evaluation of adherence of patients with asthma to treatment by single combination inhaler
Source: Eur Respir J 2006; 28: Suppl. 50, 499s
Year: 2006

How often do asthma patients claim prescribed therapy?
Source: International Congress 2017 – Asthma from childhood to adulthood and ACOS
Year: 2017


Variation of regular maintenance therapy with budesonide/formoterol of children with asthma
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008


Factors influencing LAMA addition to COPD patients receiving ICS/LABA in clinical practice-RETRIEVE study.
Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies
Year: 2021


Are COPD patients taking triple combination inhalers being overmedicated during acute exacerbations?
Source: International Congress 2019 – COPD treatment: cohorts and real-world studies
Year: 2019


Adherence with two types of inhaled corticosteroids as a primary controller regimen in adult asthma patients
Source: Eur Respir J 2002; 20: Suppl. 38, 304s
Year: 2002

Overall asthma control with budesonide/formoterol maintenance and reliever therapy in patients stratified by GINA treatment step
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Episodic high reliever use with budesonide/formoterol maintenance and reliever therapy confers added protection against asthma exacerbations
Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma
Year: 2007